Avaxia Biologics Secures $2,200,000 Series A Financing Round

  • Feed Type
  • Date
    11/10/2011
  • Company Name
    Avaxia Biologics
  • Mailing Address
    128 Spring Street Lexington, MA 02421
  • Company Description
    Avaxia is developing oral antibody products for diseases and disease targets that can be reached through the mouth and the gastrointestinal tract.
  • Website
    http://www.avaxiabiologics.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $2,200,000
  • Transaction Round
    Series A
  • Proceeds Purposes
    This investment will allow us to aggressively pursue the development of our AVX-470 anti-TNF oral antibody and prepare Avaxia to initiate a clinical trial in inflammatory bowel disease next fall.
  • M&A Terms
  • Venture Investor
    Cherrystone Angel Group
  • Venture Investor
    Boston Harbor Angels
  • Venture Investor
    Undisclosed

By posting a comment, you agree to our terms and conditions.